Clinical trial

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

NCT01096043

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Strata 1 CXL-1020 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Strata 2 CXL-1020 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Strata 3 CXL-1020 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-04-01

PhasePHASE2

Conditions

Heart Failureverified · MONDO: heart failure

Interventions

PlaceboDRUG

Strata 1 CXL-1020DRUG

Strata 2 CXL-1020DRUG

Strata 3 CXL-1020DRUG

Sponsors & collaborators

Bristol-Myers Squibblead sponsor

Cardioxyl Pharmaceuticals, Inccollaborator

Mapped research locations

DetroitMichigan, United States2 BaltimoreMaryland, United States1 ClevelandOhio, United States1 CincinnatiOhio, United States1 ColumbusOhio, United States1 JacksonvilleFlorida, United States1 OrlandoFlorida, United States1 CharlestonSouth Carolina, United States1 Winston-SalemNorth Carolina, United States1 The BronxNew York, United States1 New OrleansLouisiana, United States1 GainesvilleFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01096043 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.